Clinical trials of ovarian cancer blood test scheduled
This article was originally published in Clinica
Atairgin Technologies is to begin clinical trials of a blood test for ovarian cancer, which may be more sensitive than the commonly used CA125 test. The test measures blood levels of the biochemical marker lysophosphatidic acid (LPA). The presence of this marker is independent of the stage of tumour growth and may therefore provide an early detection tool, says the company.